CN Bio logoCN Bio logoCN Bio logoCN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix™ products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix™ support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix™ products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system

      • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place.

      • CN Bio appoints Dr Paul Brooks as Chief Executive Officer

      View all news

      Upcoming Events

      • SLAS2023

      • SOT 2023

      • WORD 2023

      • SLAS Europe 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix™ OOC Microphysiological Systems
    • Consumables
      • PhysioMimix™ multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

CN Bio Innovations announces deal with sixth pharmaceutical collaborator in 2015 and features in The Economist

CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is featured prominently in an article in the 13 June 2015 edition of The Economist. Simultaneous with the publication, CN Bio is pleased to announce that it has embarked on a joint research collaboration with a sixth pharmaceutical company since March 2015. The research will be based on CN Bio’s Quantum-B® model of Hepatitis B infection and leverage CN Bio’s expertise in cell culture and disease modelling.

June 12, 2015 by CN Bio

Welwyn Garden City, UK, 12 June 2015: CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is featured prominently in an article in the 13 June 2015 edition of The Economist newspaper.  The article, which describes the company’s organ-on-chip platform LiverChip and the associated Hepatitis B infected liver-on-a-chip model known as Quantum-B®, highlights the work of CN Bio and LiverChip® inventor Professor Linda Griffith (Massachusetts Institute of Technology) alongside other pioneers in the field including Professors Don Ingber (Harvard/Wyss Institute) and Kevin Healy (Berkeley).

Simultaneous with today’s publication, CN Bio is pleased to announce that it has embarked on a joint research collaboration with a sixth pharmaceutical company since March 2015. The research will be based on CN Bio’s Quantum-B® model of Hepatitis B infection and leverage CN Bio’s expertise in cell culture and disease modelling.

Dr Emma Sceats, CN Bio Innovations Chief Operating Officer, said “Organ-on-chips and more ambitious research such as the Defence Advanced Research Projects Agency (DARPA) human-on-a-chip program, have captured the imagination and attention of the press and general public.  To move beyond research these technologies need to be embraced by pharmaceutical companies and regulators alike, and CN Bio’s success in securing a sixth pharmaceutical partner for its Quantum-B® technology is evidence of our significant progress in that regards.”

The Economist is a business and world affairs newspaper with a weekly global circulation in excess of 1.5 million copies.  The full organ-on-chips article is available on The Economist website, here.

Category iconBusiness

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

+44 (0) 1223 737941

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023
  • CN Bio appoints Dr Paul Brooks as Chief Executive Officer December 19, 2022

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SLAS2023 February 25 - March 1, 2023